Abstract:
Background: Many cohorts show effectiveness of all-oral direct acting antivirals (DAA) for HCV therapy >90%. Few studies focus on predictive factors of failure in HIV coinfection. Methods: Patients and desing: Observational prospective study in HIV/HCV coinfected patients of the “VIH-DOC” cohort treated with all-oral DAA between January 9, 2015, and August 31, 2016. Analysis: - Sustained virological response (SVR) was analyzed 24 weeks after the end of therapy in the intention to treat population. - SVR proportions were compared by the Fisher exact test in different subgroups (Table 1). - Binary logistic regression was used for multivariate analysis (backward stepwise). It included clinically relevant variables (cirrhosis, response to previous interferon therapy and IL28B polymorphism), and factors with a Fisher test p value < 0.15